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Multi-target therapies, either in combination or in sequential order, have been advocated to
combat intrinsic and acquired resistance to anti-cancer drugs (Holohan et al., 2013; Yardley, 2013).
However, the effectiveness of multi-target anti-cancer therapy in the clinic is limited. The selection
of cancer cells obeys Darwin’s law of evolution. Under the pressure of drug perturbation, the cancer
cell can adapt versatile molecular and cellular mechanisms for survival, and often evolves into
more aggressive or metastasis phenotypes (Holohan et al., 2013). At the molecular level, acquired
mutations resulting from drug treatment may modify drug metabolism (e.g., increasing efflux,
decreasing uptake, and enhancing detoxification etc.) and alter drug-target interactions. At the
cellular level, multiple pathways support the survival of cancer cells. The inhibition of one pathway
may result in the activation of an alternative pathway. Although novel approaches to optimizing
combination therapies have been proposed to defer these drug resistance mechanisms (Crystal
et al., 2014; Wang et al., 2015), intra-tumor heterogeneity that have been observed ubiquitously
may make the drug combination fail (McGranahan and Swanton, 2015). Polygenic drug-resistance
mechanisms are present in sub-clones prior to the initiation of therapy (Bozic et al., 2013). If the
therapy cannot target all sub-clones that drive the cancer progress in a fast-killing mode, it would
prompt the rapid growth of sub-clones that are not sensitive to the treatment (Gatenby et al., 2009).
Unfortunately, the number of driver mutations in advanced tumors is substantial (Gerlinger et al.,
2014). It could be an impossible mission to target all driver mutations. The existence of cancer stem
cells adds another dimension of complexity. The conventional single or combinational anti-cancer
drug is incapable of killing cancer stem cells. When a cancer cell is killed by chemotherapy, it could
send signals to stimulate the proliferation of the cancer stem cell, leading to the repopulation of the
drug-resistance tumor (Kurtova et al., 2015). Thus, new strategies are needed to combat anti-cancer
drug resistance with the goal to improve the effectiveness of anti-cancer therapy.
Cancer cells originate from the host’s normal cells, but eventually turn into a new “pathogen”
species. To eliminate anti-cancer drug resistance, we may borrow an idea from anti-bacterial
drug discovery. Anti-virulence has emerged as a novel concept in addressing the challenge of
antibiotic resistance (Rasko and Sperandio, 2010). Instead of killing bacteria, the anti-virulence
drug interferes with the bacterial virulence and/or cell-cell communication, disrupts pathogen-
human interactions, or enhances the host’s inner immunity. The rationale is that the bacterium is
less likely to evolve into a drug-resistant strain when facing less evolutionary pressure. As the cancer
adapts similar mechanisms to the bacterium in acquiring drug resistance, the “anti-virulence”
strategy could be applied as an anti-cancer therapy. Recent successes in anti-cancer immune
therapy open a new door to exploring the “anti-virulence” strategy in cancer treatment (Johnson
et al., 2015). If the cancer can be controlled as a less aggressive or non-metastasis type, it may be
possible to cure the cancer by boosting anticancer immunity (Carmi et al., 2015). On the contrary,
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the chemotherapy may stimulate the production of
immunosuppressive molecules (Shalapour et al., 2015). As
a result, the patient’s anti-cancer immune response is inhibited.
Along these lines, adaptive therapy has been proposed to control
the tumor growth by permitting the survival of drug sensitive
cells. In this way, the growth of drug-resistant clones could be
surpassed (Gatenby et al., 2009). In some cases, the cancer can
be treated as a chronic disease when transferring the cancer
cell into a quiescent state (Aguirre-Ghiso, 2006). For example,
chronic myeloid leukemia (CML), chronic lymphocytic leukemia
(CLL), and low grade non-Hodgkin’s lymphoma (NHL) are
slow-growing cancers. Patients can live with them for many
years.
The various heterogeneous types of cancer cells form an
ecosystem, cooperating and competing with each other for
nutrients and spaces from the harsh environment. For example,
sustained angiogenesis, one of the hallmarks of cancer, relies on
the cooperation of co-existing cell lineages (Floor et al., 2012).
The cooperating sub-clones either bear complementary traits
or play a different role of producer or consumer of “public
goods” such as diffusible growth factors (Korolev et al., 2014).
Based on theoretical, experimental, and clinical results of ecology,
microbiology, and cancer research, it has been proposed that
tuning the population dynamics of cancer cells can be a powerful
strategy in developing an anti-cancer therapy (Korolev et al.,
2014). By either changing the tumor microenvironment, or
confusing cancer cell-cell communications, the whole cancer
ecosystem can be controlled, even eliminated.
To determine the evolutionary dynamics of the cancer
ecosystem, and the drug targets that can modulate its
evolutionary trajectory, we need a deep understanding of not
only the drug response and resulting evolution of individual
cell types but also the emergent properties of the whole system
under a diverse genetic and environmental background, which
is more than a simple summarization of the behavior of all
cells. Recent advances in cancer biology, single cell technologies,
next-generation sequencing, and systems biology provide great
opportunities to dissect the evolution of the cancer ecosystem
at multiple scales. Multiple molecular components such as
integrin and cadherin and pathways (e.g., Rho GTPase), which
are responsible for the cell-cell communications and the cell-
environment interactions, have been revealed (Brücher and
Jamall, 2014). They represent potential drug targets to perturb
cancer cell-cell interactions and to constraint tumor growth.
The Cancer Genome Atlas has identified millions of somatic
mutations (Ledford, 2015). Correlated with generic variations,
drug response phenomics data are available at molecular,
cellular, tissue, and organism levels (Zbuk and Eng, 2007). The
systematic integration of these data may allow us to predict drug-
response phenotypes for intervention against multiple targets
and pathways. Single cell sequencing has revealed the clonal
evolution of breast cancer (Wang et al., 2014) and childhood
acute lymphoblastic leukemia (Gawad et al., 2014), and drug
resistance dynamics (Lee et al., 2014). These studies will provide
critical information to predict the cancer evolutionary trajectory,
leading to the development of pre-emptive treatment strategies
that are in contrast to current reactive clinical approaches. In
spite of this progress, one of fundamental challenges remaining
is to bridge genetic and molecular mechanisms of single cell-cell
interactions to the ecological dynamics of the cancer population.
Multi-scale modeling and simulation may play a key role in
predicting the evolutionary dynamics of the cancer ecosystem,
and identify anti-cancer therapeutic targets for pre-emptive
treatment. It is possible to reconstruct context-specific whole
cell models by integrating multiple omics data (Karr et al.,
2012). Subsequently, their cellular functions can be simulated and
predicted at different evolutionary stages under a framework of
constraint-based modeling (Bordbar et al., 2014). Using a single
cell or sub-clone as the building block, the cancer ecosystem
can be modeled as a dynamic cell-cell interaction network, in
which the node is a cell, and the edge represents the cell-
cell interaction. Each node, or cluster of nodes, has different
traits and evolutionary trajectory, yet depend on each other, as
shown in Figure 1. A network representation may allow us to
understand the emergent properties of the cancer ecosystem.
For example, one of intrinsic properties of biological network
is “robust-yet-fragile” (Kitano, 2007). The removal of a single
node may have little impact on the whole system. However,
the weak perturbation of multiple nodes can lead to the system
failure, even if these nodes are not deleted. A number of
effective therapies in treating complex diseases may follow this
principle (Xie et al., 2012). For instance, successful anti-psychotic
drugs, such as clozapine, mediate their effects through binding
entire families of serotonin and dopamine receptors. The clinical
failures of many anti-psychotic drugs can be attributed to them
being too selective as designed (Hopkins et al., 2006). In another
example, the anti-cancer effect of HIV protease inhibitors is
proposed to comes from their weak bindings to multiple kinases
(Xie et al., 2011). Moreover, the perturbation of edges may be
more effective than nodes to regulate the state transition of a
non-linear dynamic system (Tong et al., 2012). An additional
advantage of edge perturbation is that the cancer cell has little
selection pressure to evolve into a drug resistant phenotype,
as the cancer cell will not be killed directly by the drug.
In a proof-of-concept study, blocking cell-cell communication
inhibited the repopulation of cancer stem cells, thus enhancing
the effectiveness of anti-cancer therapy (Kurtova et al., 2015). To
capture the whole dynamic spectrum of the cancer ecosystem,
mechanistic and quantitative dynamic simulation is needed.
Coarse-grained dynamic modeling has successfully identified
an optimized sequence of therapies to improve the survival
of patients with metastatic castrate resistant prostate cancer
(Gallaher et al., 2014). Agent-based modeling that has been
successfully applied to study the dynamics of complex systems
could be a powerful tool to integrate whole cell models into a
dynamic model of the cancer ecosystem (An et al., 2009).
Multi-target therapy can be achieved by either
polypharmacology or drug combination. Polypharmacology
has several advantages over drug combination. Firstly, it is
not a trivial task to optimize dosages and sequences of a drug
combination. The highly heterogeneous nature of cancer cells
makes optimization even more difficult. Secondly, potential
drug-drug interactions may cause serious side-effects. A singe
“dirty” drug may reduce the probability of this problem. Finally,
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FIGURE 1 | Two strategies for anti-cancer therapy. (A) Node killing strategy kills sub-clones of cancer cells through chemo-, targeted-, and immuno-therapy. The
adaptive evolution of the cancer often leads to drug resistance. The cancer often turns into a more aggressive form. (B) Edge perturbation strategy aims to disturb the
cell-cell interactions of the cancer ecosystem. It may have bigger impact on the cancer as a whole. It is less likely for the cancer to evolve into a drug resistance
phenotype, as no sub-clone can gain particular evolutionary advantage.
it is argued that polypharmacology is more likely to achieve
desired selective profiles than the drug combination (Varshavsky,
1998). Compared with anti-virulence agents for bacteria,
selectivity is particularly challenging in the development of
anti-cancer therapy, as the normal cell is more similar to the
cancer cell than the bacteria. The side-effect of anti-cancer
therapy is mainly because the drug cannot distinguish the
normal cell from the cancer cell. The cancer genes that harbor
driver mutations can be either up-regulated or down-regulated.
A polypharmacological agent can be designed in such a way that
it is mutually exclusive—it binds both the up-regulated gene A
and the down-regulated gene B (terms A+ and B-, respectively)
(Varshavsky, 1998). Consequently, the agent will selectively bind
to A+ in the cancer cell as B- is less competitive. In the normal
cell, A and B will competitively bind the agent, thus the agent
will have little impact on the function of either of them. In
contrast, the combination of two drugs, which bind to A and B,
respectively, will be less selective. Following the same principle
above, a selective agent can be designed for genes that are all
up-regulated through targeting the allosteric site of one gene
(Varshavsky, 1998).
The identification of suitable therapeutic targets is only
the starting point of anti-cancer drug development. It is
often more challenging to discover molecules that are able
to achieve desirable therapeutic effects with minimum side
effects. In addition to conventional druggable targets, targeting
the protein-protein interaction (PPI) interface could be an
efficient strategy to modulate signal transduction, cell-cell
communications, and cell-environmental interactions (Jubb
et al., 2012; Mullard, 2012). For example, cadherin-p120
interactions may mediate the contact inhibition of locomotion
(CIL) that controls cell growth. The loss of CIL leads to
tumor growth and metastasis (Mayor and Carmona-Fontaine,
2010). Thus, enhancing cancer cell-cell interactions may inhibit
tumor progression. Historically, it is difficult to design small
molecule inhibitors to target the PPI interface, as it is flat,
large, and featureless, and thus considered undruggable. Multiple
weak binders instead of a single strong binder could be an
alternative strategy to designing PPI modulators, as the PPI
interface is characterized by “hot spots” that contribute the
most to the binding free energy, and well-defined grooves or
small pockets that are associated with a continuous epitope
binding partner (Ma and Nussinov, 2014). As mentioned
previously, multiple weak binders may be more effective in
regulating biological systems than a single selective inhibitor
with high binding affinity. Although drug combinations are
a successful multi-target therapy strategy, possible drug-drug
interactions may limit the number of drugs administrated
together. Polypharmacology offers two alternatives to the
drug combination. Polypharmacology aims to design “dirty”
drugs that can bind to multiple receptors simultaneously. Its
effectiveness in treating systematic diseases has been documented
(Xie et al., 2012). For example, targeted polypharmacological
agents have been successfully designed to modulate signaling
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transduction events (Apsel et al., 2008). It is possible for a
small molecule to target multiple PPI interfaces, as they are
promiscuous across fold space (Gao and Skolnick, 2010), and
may share conserved hot spot residues (Keskin et al., 2005;
Shulman-Peleg et al., 2007). The desired multi-target binding
specificity can be achieved through the fine-tuned side chain
geometry and chemistry of protein-ligand interactions (Gao and
Skolnick, 2010).
In summary, with advances in whole genome sequencing,
high-throughput techniques, systems biology, and cloud
computing, information on the evolutionary dynamics of cancer,
from a single cell to the whole population, is starting to emerge.
Concurrently, progress in medicinal chemistry is expanding
the druggable target space (e.g., through targeting the protein-
protein interaction interface and allosteric events). Putting these
efforts together may open a new door to multi-target therapies
for cancer treatment.
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